MedTrace Logo

Study of Brain Imaging With Nuclear Technology in Individuals With Parkinsonian Syndrome

NCT00132626 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 500

Last updated 2019-04-03

No results posted yet for this study

Summary

This study assesses dopamine transporter density using single photon emission computed tomography (SPECT) brain imaging with an investigational radiopharmaceutical, \[123I\]ß-CIT, in research participants with Parkinson's disease.

Conditions

Interventions

DRUG

[123I]ß-CIT and SPECT imaging

Sponsors & Collaborators

  • Molecular NeuroImaging

    collaborator OTHER

  • National Institutes of Health (NIH)

    collaborator NIH

  • Institute for Neurodegenerative Disorders

    lead OTHER

Principal Investigators

  • Kenneth Marek, MD · Institute for Neurodegenerative Disorders

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
35 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1992-09-30
Completion
2005-08-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00132626 on ClinicalTrials.gov